DIADS-2Depression in Alzheimer's Disease (DIADS-2)
Sertraline (Zoloft)
+ Placebo
Alzheimer Disease+9
+ Behavior
+ Mental Disorders
Treatment Study
Summary
Study start date: July 1, 2004
Actual date on which the first participant was enrolled.Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks. Visits include neuropsychological testing. Caregivers are asked to are the patient on a Daily Affect Diary for 6 weeks during the study period. Telephone followup is done at weeks 36 and 48. Both groups receive caregiver support/education.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.131 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion: * Ability of the participant, caregiver or surrogate to provide written informed consent. * Dementia due to Alzheimer's disease * Stable treatment for Alzheimer's disease * Ability for the participant's caregiver to accompany the participant to study visits and participate in the study. Exclusion * Presence of a brain disease that might otherwise explain the presence of dementia * Clinically significant hallucinations or delusions * Current treatment of antipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications * Need for hospitalization or residence in a nursing facility
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 5 locations
University of Southern California
Los Angeles, United StatesOpen University of Southern California in Google MapsJohns Hopkins Hospital
Baltimore, United StatesUniversity of Rochester
Rochester, United StatesUniversity of Pennsylvania
Philadelphia, United States